全文获取类型
收费全文 | 1189篇 |
免费 | 76篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 37篇 |
妇产科学 | 21篇 |
基础医学 | 140篇 |
口腔科学 | 31篇 |
临床医学 | 144篇 |
内科学 | 173篇 |
皮肤病学 | 71篇 |
神经病学 | 111篇 |
特种医学 | 57篇 |
外科学 | 126篇 |
综合类 | 35篇 |
预防医学 | 124篇 |
眼科学 | 80篇 |
药学 | 82篇 |
中国医学 | 2篇 |
肿瘤学 | 28篇 |
出版年
2022年 | 15篇 |
2021年 | 18篇 |
2020年 | 14篇 |
2018年 | 21篇 |
2017年 | 13篇 |
2016年 | 20篇 |
2015年 | 10篇 |
2014年 | 19篇 |
2013年 | 25篇 |
2012年 | 42篇 |
2011年 | 50篇 |
2010年 | 22篇 |
2009年 | 39篇 |
2008年 | 42篇 |
2007年 | 62篇 |
2006年 | 41篇 |
2005年 | 41篇 |
2004年 | 44篇 |
2003年 | 54篇 |
2002年 | 54篇 |
2001年 | 37篇 |
2000年 | 26篇 |
1999年 | 32篇 |
1998年 | 14篇 |
1997年 | 13篇 |
1995年 | 12篇 |
1992年 | 16篇 |
1991年 | 21篇 |
1990年 | 23篇 |
1989年 | 17篇 |
1988年 | 19篇 |
1987年 | 38篇 |
1986年 | 32篇 |
1985年 | 33篇 |
1984年 | 36篇 |
1983年 | 20篇 |
1982年 | 22篇 |
1981年 | 17篇 |
1980年 | 10篇 |
1979年 | 13篇 |
1978年 | 10篇 |
1976年 | 9篇 |
1975年 | 9篇 |
1974年 | 10篇 |
1973年 | 9篇 |
1972年 | 9篇 |
1971年 | 9篇 |
1968年 | 12篇 |
1967年 | 17篇 |
1966年 | 11篇 |
排序方式: 共有1270条查询结果,搜索用时 15 毫秒
101.
102.
Young KA Parrish LA Zerbe GO Rewers M Deane KD Michael Holers V Norris JM 《Annals of the rheumatic diseases》2007,66(2):179-183
OBJECTIVE: To examine perinatal and childhood risk factors for the presence of rheumatoid factor in healthy children. METHODS: The Diabetes Autoimmunity Study in the Young (DAISY) is a longitudinal study of children at increased risk of type 1 diabetes, based on possession of human leucocyte antigen (HLA)-DR4 and DR3 alleles or a family history of diabetes. 651 children who participated in DAISY, with an average age of 6.4 (range 1-15) years, were tested for the presence of rheumatoid factor in their most recent serum sample. 23 children were positive for rheumatoid factor. Exposure data were collected prospectively by interview. HLA-DR4 alleles were identified using polymerase chain reaction-based Class II genotyping. RESULTS: While exploring risk factors for rheumatoid factor positivity in a multivariate model, several important interaction terms involving HLA-DR4 status suggested the need to evaluate risk factors in HLA-DR4-positive and HLA-DR4-negative children separately. In HLA-DR4-negative children, rheumatoid factor-positive infants were less likely to have been breast fed for >3 months (odds ratio (OR) 0.18; 95% confidence interval (CI) 0.04 to 0.99), more likely to have been exposed to non-parental tobacco smoke (OR 5.38; 95% CI 0.93 to 31.27) and more likely to be a race/ethnicity other than non-Hispanic white (OR 6.94; 95% CI 1.10 to 43.88) compared with rheumatoid factor-negative children, after adjusting for age, sex and maternal education. In HLA-DR4-positive children, there were no significantly associated risk factors for rheumatoid factor positivity. CONCLUSIONS: Risk factors for rheumatoid factor positivity in children vary by HLA-DR4 genotype. In HLA-DR4-negative children, breast feeding may decrease the risk, and environmental tobacco smoke may increase the risk, of autoimmunity. 相似文献
103.
Froimowitz M Gu Y Dakin LA Nagafuji PM Kelley CJ Parrish D Deschamps JR Janowsky A 《Journal of medicinal chemistry》2007,50(2):219-232
Methylphenidate analogues, in which the carbomethoxy has been replaced by an alkyl group and with different phenyl substituents, have been synthesized and tested in monoamine transporter assays. As predicted from a pharmacophore model, most of the RR/SS diastereomers showed high potency as dopamine reuptake inhibitors. Analogues with a 4-chlorophenyl group and an unbranched initial alkyl atom had consistently enhanced selectivity for the dopamine transporter. The most potent compounds were those with a three- or four-carbon chain. The "inactive" RS/SR diastereomers showed substantial activity when the phenyl substituent was 3,4-dichloro. On a locomotor assay, one compound was found to have a slow onset and a long duration of action. The activity of these compounds provides additional evidence for a conformational/superposition model of methylphenidate with cocaine-like structures. A ketone analogue, obtained by hydrogenating a previously described vinylogous amide, had activity similar to that of methylphenidate. 相似文献
104.
Hiebel AC Lee YS Bilsky E Giuvelis D Deschamps JR Parrish DA Aceto MD May EL Harris LS Coop A Dersch CM Partilla JS Rothman RB Cheng K Jacobson AE Rice KC 《Journal of medicinal chemistry》2007,50(16):3765-3776
Both of the enantiomers of 5-(3-hydroxyphenyl)-N-phenylethylmorphan with C9alpha-methyl, C9-methylene, C9-keto, and C9alpha- and C9beta-hydroxy substituents were synthesized and pharmacologically evaluated. Three of the 10 compounds, (1R,5R,9S)-(-)-9-hydroxy-5-(3-hydroxyphenyl-2-phenylethyl-2-azabicyclo[3.3.1]nonane ((1R,5R,9S)-(-)-10), (1R,5S)-(+)-5-(3-hydroxyphenyl)-9-methylene-2-phenethyl-2-azabicyclo[3.3.1]nonane ((1R,5S)-(+)-14), and (1R,5S,9R)-(-)-5-(3-hydroxyphenyl)-9-methyl-2-phenethyl-2-azabicyclo[3.3.1]nonane ((1R,5S,9R)-(+)-15) had subnanomolar affinity at mu-opioid receptors (Ki = 0.19, 0.19, and 0.63 nM, respectively). The (1R,5S)-(+)-14 was found to be a mu-opioid agonist and a mu-, delta-, and kappa-antagonist in [35S]GTP-gamma-S assays and was approximately 50 times more potent than morphine in a number of acute and subchronic pain assays, including thermal and visceral models of nociception. The (1R,5R,9S)-(-)-10 compound with a C9-hydroxy substituent axially oriented to the piperidine ring (C9beta-hydroxy) was a mu-agonist about 500 times more potent than morphine. In the single-dose suppression assay, it was greater than 1000 times more potent than morphine. It is the most potent known phenylmorphan antinociceptive. The molecular structures of these compounds were energy minimized with density functional theory at the B3LYP/6-31G* level and then overlaid onto (1R,5R,9S)-(-)-10 using the heavy atoms in the morphan moiety as a common docking point. Based on modeling, the spatial arrangement of the protonated nitrogen atom and the 9beta-OH substituent in (1R,5R,9S)-(-)-10 may facilitate the alignment of a putative water chain enabling proton transfer to a nearby proton acceptor group in the mu-opioid receptor. 相似文献
105.
106.
Brad Wright PhD Canada Parrish PhD MSPH Anirban Basu PhD MS Karen E. Joynt Maddox MD MPH Joshua M. Liao MD. MSc Amber K. Sabbatini MD MPH 《Health services research》2023,58(3):554-559
Objective
To evaluate whether Medicare's Hospital Readmissions Reduction Program (HRRP) is associated with increased observation stay use.Data Sources and Study Setting
A nationally representative sample of fee-for-service Medicare claims, January 2009–September 2016.Study Design
Using a difference-in-difference (DID) design, we modeled changes in observation stays as a proportion of total hospitalizations, separately comparing the initial (acute myocardial infarction, pneumonia, heart failure) and subsequent (chronic obstructive pulmonary disease) target conditions with a control group of nontarget conditions. Each model used 3 time periods: baseline (15 months before program announcement), an intervening period between announcement and implementation, and a 2-year post-implementation period, with specific dates defined by HRRP policies.Data Collection/Extraction Methods
We derived a 20% random sample of all hospitalizations for beneficiaries continuously enrolled for 12 months before hospitalization (N = 7,162,189).Principal Findings
Observation stays increased similarly for the initial HRRP target and nontarget conditions in the intervening period (0.01% points per month [95% CI −0.01, 0.3]). Post-implementation, observation stays increased significantly more for target versus nontarget conditions, but the difference is quite small (0.02% points per month [95% CI 0.002, 0.04]). Results for the COPD analysis were statistically insignificant in both policy periods.Conclusions
The increase in observation stays is likely due to other factors, including audit activity and clinical advances. 相似文献107.
108.
Cristina Rosas Gerlinde R Van de Walle Stephan M Metzger Karin Hoelzer Edward J Dubovi Sung G Kim Colin R Parrish Nikolaus Osterrieder 《Vaccine》2008,26(19):2335-2343
In 2004, canine influenza virus (CIV) was identified as a respiratory pathogen of dogs for the first time and found to be closely related to H3N8 equine influenza virus (EIV). We generated a recombinant vectored vaccine that expresses H3 of a recent isolate of EIV using equine herpesvirus type 1 (EHV-1) as the delivery vehicle. This EHV-1 vectored vaccine exhibited robust and stable EIV H3 expression and induced a strong influenza virus-specific response in both mice and dogs upon intranasal or subcutaneous administration. Furthermore, upon challenge with the recent CIV isolate A/canine/PA/10915-07, protection of vaccinated dogs could be demonstrated by a significant reduction in clinical sings, and, more importantly, by a significant reduction in virus shedding. We concluded that the EHV-1/H3 recombinant vector can be a valuable alternative for protection of dogs against clinical disease induced by CIV and can significantly reduce virus spread. 相似文献
109.
110.